Cargando…

Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation

BACKGROUND: Epithelial-mesenchymal transition (EMT) played an important role in the progression of hepatocellular carcinoma (HCC) after insufficient radiofrequency ablation (RFA). However, whether sorafenib could be used to suppress the EMT of HCC after insufficient RFA and further prevent the progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Shuying, Kong, Jian, Kong, Fandong, Kong, Jinge, Gao, Jun, Ji, Liang, Pan, Bing, Chen, Lian, Zheng, Lemin, Sun, Wenbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663721/ https://www.ncbi.nlm.nih.gov/pubmed/26620566 http://dx.doi.org/10.1186/s12885-015-1949-7

Ejemplares similares

Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways
por: Dong, Shuying, et al.
Publicado: (2013)

ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy
por: Kong, Jian, et al.
Publicado: (2020)

Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1α/VEGFA
por: Kong, Jian, et al.
Publicado: (2012)

After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma
por: Kong, Jian, et al.
Publicado: (2012)

Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation
por: Zhang, Qingyun, et al.
Publicado: (2017)

Circular BANP knockdown inhibits the malignant progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation
por: Li, Guoming, et al.
Publicado: (2022)

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma
por: Kong, Jian, et al.
Publicado: (2014)

ICAM‐1 Activates Platelets and Promotes Endothelial Permeability through VE‐Cadherin after Insufficient Radiofrequency Ablation
por: Kong, Jian, et al.
Publicado: (2021)

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research
por: Wu, Shilun, et al.
Publicado: (2022)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation
por: Guo, Yusheng, et al.
Publicado: (2022)

Platelet lysates in Hepatocellular Carcinoma patients after radiofrequency ablation facilitate tumor proliferation, invasion and vasculogenic mimicry
por: Jia, Guoqun, et al.
Publicado: (2020)

Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation
por: Gong, Quanyou, et al.
Publicado: (2017)

Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway
por: Xu, Wen-Lei, et al.
Publicado: (2019)

Radiofrequency Ablation of the Main Lesion of Hepatocellular Carcinoma and Bile Duct Tumor Thrombus as a Radical Therapeutic Alternative: Two Case Reports
por: Gao, Jun, et al.
Publicado: (2015)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Radiofrequency Ablation Versus Reresection in Treating Recurrent Hepatocellular Carcinoma: A Meta-Analysis
por: Cai, Hao, et al.
Publicado: (2014)

The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma
por: Yan, Shi-Yan, et al.
Publicado: (2016)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation
por: Liang, Xuexia, et al.
Publicado: (2023)

Treatment of Insulinomas by Laparoscopic Radiofrequency Ablation: Case Reports and Literature Review
por: Yao, Changyu, et al.
Publicado: (2020)

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy
por: Wei, Meng-Chao, et al.
Publicado: (2022)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Liao, Li-Zhu, et al.
Publicado: (2020)

PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition
por: Liu, Hongyu, et al.
Publicado: (2019)

Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Zhang, Shidong, et al.
Publicado: (2020)

Complications of Radiofrequency Ablation for Hepatic Hemangioma: A Multicenter Retrospective Analysis on 291 Cases
por: Wu, Shilun, et al.
Publicado: (2021)

Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3
por: Zhang, Ning, et al.
Publicado: (2017)

Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins
por: Zhang, Ning, et al.
Publicado: (2019)

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma
por: Kwak, Min Hwan, et al.
Publicado: (2022)

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
por: Fouquet, Grégory, et al.
Publicado: (2022)

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Wang, Shanshan, et al.
Publicado: (2023)

Correlations between chromobox homolog 8 and key factors of epithelial–mesenchymal transition in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2019)

Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates
por: Liu, Lei, et al.
Publicado: (2020)

Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop
por: Wang, Xiaofei, et al.
Publicado: (2018)

Radiofrequency Thermal Ablation of Hepatocellular Carcinomas
por: Lim, Hyo Keun
Publicado: (2000)

Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor
por: Modi, Siddharth J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2if9fp2kmj5ad85buu4g658i15